By continuing to use this website, you agree to our Cookies Policy

ACCEPT
Policy

Daniel Kelly, European Cancer Summit 2021: Eliminating HPV Cancers

Published Online: November 15th 2021

We were delighted to catch up with Prof Daniel Kelly (Cardiff University, Wales, UK) to discuss the latest policy developments in the mission of HPV cancer elimination and the gender neutral vaccination plan.

Questions
1. How are the World Health Organisation and Europe’s Beating Cancer Plan working together to tackle HPV-associated cancers? (00:20-01:18)
2. What has been the impact of the HPV vaccine in terms of cancer prevention? (01:18-02:28)
3. What are the hopes for gender neutral vaccination? (02:28-03:38)
4. Could you tell us a little about the European Cancer Organisation’s HPV Action Network and its aims? (03:38-04:43)
5. How is the HPV Action Network working to improve gender neutral vaccination availability across Europe? (04:43-05:47)

Speaker Disclosure: Daniel Kelly has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the European Cancer Summit 2021

Share this Video
Related Videos In Policy
Policy
Developed by Touch
Bart Westerman, AACR 2022: An AI Model to Predict Adverse Drug Reactions

We were delighted to catch up with Dr. Bart Westerman (VU Medical Center, Amsterdam UMC, Amsterdam, The Netherlands) to discuss his presentation entitled ‘An AI Model Can Help Predict Adverse Events From New Drug Combinations’, which was presented at AACR 2022, 8-13 April 2022. Questions Why is it important to better predict the benefit-risk profile […]

Policy
Why Should Healthcare Professionals visit touchONCOLOGY.com and read touchREVIEWS in Oncology & Haematology?
Policy
Andreas Charalambous Discusses His Hopes as President of the European Cancer Organisation

Dr Andreas Charalambous discusses his hopes and priorities for his tenure as President of the European Cancer Organisation, beginning in January 2022. Questions 1. What do you hope to accomplish during your tenure as president of the European Cancer Organisation? (00:27-02:18) 2. What will be your immediate priorities as president? (02:18-05:06) Speaker Disclosure: Andreas Charalambous […]

Trending In Policy:

Bart Westerman, AACR 2022: An AI Model to Predict Adverse Drug Reactions
Policy
    • social_linkedin_altaccredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavataravatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubesponsored shape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12NEW TMM Corporate Services Icons-13Artboard ? NEW TMM Corporate Services Icons-15 Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72TMM-Corp-Site-Icons-73